(Total Views: 367)
Posted On: 10/16/2025 2:27:48 AM
Post# of 157998
seemingly,
Your comment
In addition, if the protocol for any reason prohibits use of an ICI upon upregulation of PDL-1, then we need not be too surprised at the slow pace of enrollment as it is unlikely that desperate folks would participate in such a restrictive trial. AND, if they did submit to that restriction at the beginning, the trial might end with MASS DE-ENROLLMENT of participants for the ethical breach that would exist when leronlimab works as expected!
As a side note to all of the board members, who are such great friends of Nader Pourhassan, it is clear that, unless Cytodyn has manufactured more leronlimab, our former CEO saved your asses.
Peace
Your comment
Quote:is a probable outcome if the protocol prohibits use of an ICI upon proven upregulation of PDL-1. I do not clearly understand what the trial protocol requires with increased PDL-1, but would be surprised if Lalezari, et al, have not begun or completed that discussion with the FDA.
...i would yank them out of the trial that very day...
In addition, if the protocol for any reason prohibits use of an ICI upon upregulation of PDL-1, then we need not be too surprised at the slow pace of enrollment as it is unlikely that desperate folks would participate in such a restrictive trial. AND, if they did submit to that restriction at the beginning, the trial might end with MASS DE-ENROLLMENT of participants for the ethical breach that would exist when leronlimab works as expected!
As a side note to all of the board members, who are such great friends of Nader Pourhassan, it is clear that, unless Cytodyn has manufactured more leronlimab, our former CEO saved your asses.
Peace
(2)
(0)
